Some of Oncotarget articles on cancer focuses on strategies of pro-oncogenic cell signaling devices to address issues of human malignancies. This focus on a particular cancer cell may have identified both gene and drug therapy methods that can be used in treatment and prevention. The medical journal focuses on providing comprehensive information about the translational strategy that fights oncolytic infections. Check Oncotarget at scimagojr.com
Pro-oncogenic signals are the pathway that generates cancer in humans. The development of mutant versions of HSV-1 is a significant milestone in Oncolytic microbes research. The Ras-Smart virus is known as “ Signal Smart 1”. SS1 mutant is a different model of Oncolytic microbes that is designed to attack Cancer Stem Cells (CSCs) on tissue in a particular way.
Oncotarget uses state of the art submission and manuscript tracking software – https://t.co/LZQlbzuW34
— Oncotarget (@OncotargetJrnl) December 14, 2017
HSV-1 and SS1 viruses are designed to remove all cancer stem cells that may have tumors. The CSC is a class of cells that can repopulate tumors and support different varieties of cells which make up the histological structures of cancer. No other therapy can efficiently eliminate CSCs in the body. The use of Oncolytic microbes is the best cancer therapy to prevent repopulating tumors in humans.
Most of the tumor antigens are known to be “self –antigens” making anti-tumor immune reactions face some inherent problems. Anti-cancer T cells prevent the formation of protective anti-cancer immunity. CD4 T cell can be used by doctors to facilitate the creation of specific reaction of antigen CD8+ cytolytic T lymphocyte (CTL).
Other approaches that can be used to restrict CSCs cells from multiplying include, generation of immunogenic DC that make inhibitory molecules such as IL-10; HSV-VP22 and carrier protein for simultaneous production of CD8 T and CD4 T cell response; utilization of “self-translatable.” The formation of specific donor customized MHC class 1 controlled anti-tumor CD8+ CTL and CD4+ “multifunctional” T cells by creating human peripheral blood obtained from T cells with an MHC class 1 prevented transgenic T cell receptor( TCR), separated from melanoma patient-derived CD8 + CTL.
Onctotarget researchers have consistently sought to produce valuable information regarding cancer treatment and biological processes. Their continued hard work provides options for patients and paves the way to the future of oncology treatments. Learn more at Research Gate.